Vulvovaginal Candidiasis - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 43 Pages - SKU: GMD6776078
|
|
Vulvovaginal Candidiasis - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Vulvovaginal Candidiasis - Pipeline Review, H1 2012', provides an overview of the Vulvovaginal Candidiasis therapeutic pipeline. This report provides information on the therapeutic development for Vulvovaginal Candidiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vulvovaginal Candidiasis. 'Vulvovaginal Candidiasis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Vulvovaginal Candidiasis.
- A review of the Vulvovaginal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vulvovaginal Candidiasis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Vulvovaginal Candidiasis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Vulvovaginal Candidiasis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Vulvovaginal Candidiasis
- Vulvovaginal Candidiasis Therapeutics under Development by Companies
- Vulvovaginal Candidiasis Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Pre-Clinical Stage Products
- Comparative Analysis
- Vulvovaginal Candidiasis Therapeutics - Products under Development by Companies
- Vulvovaginal Candidiasis Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Vulvovaginal Candidiasis Therapeutics Development
- Merck & Co., Inc.
- MethylGene Inc
- Pevion Biotech Ltd
- Ferrer Internacional S.A.
- Vulvovaginal Candidiasis - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Arasertaconazole - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PEV7 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MGCD290 + Fluconazole - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Lavender Vaginal Cream - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Ketoconazole + Clindamicyn - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Butoconazole Nitrate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- r-MP65 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Vulvovaginal Candidiasis Therapeutics - Drug Profile Updates
- Vulvovaginal Candidiasis Therapeutics - Discontinued Products
- Vulvovaginal Candidiasis Therapeutics - Dormant Products
- Vulvovaginal Candidiasis - Product Development Milestones
- Featured News & Press Releases
- Jan 17, 2012: Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory In All Vaccinees
- Oct 11, 2011: Pevion’s Therapeutic Candida Vaccine PEV7 Shows Robust Systemic And Mucosal Immunogenicity
- Sep 01, 2011: Pevion Grants CSL Option Right To Therapeutic Candida Vaccine
- Nov 11, 2010: Pevion Announces Positive Preliminary Results From Phase I Study Of PEV7 In Recurrent Vulvovaginal Candidiasis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Vulvovaginal Candidiasis, H1 2012
- Products under Development for Vulvovaginal Candidiasis - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Comparative Analysis by Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Merck & Co., Inc., H1 2012
- MethylGene Inc, H1 2012
- Pevion Biotech Ltd, H1 2012
- Ferrer Internacional S.A., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Vulvovaginal Candidiasis Therapeutics - Drug Profile Updates
- Vulvovaginal Candidiasis Therapeutics - Discontinued Products
- Vulvovaginal Candidiasis Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for Vulvovaginal Candidiasis, H1 2012
- Products under Development for Vulvovaginal Candidiasis - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Obstetrics/Gynecology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
